VRTX Stock Cash Flow Statements

Vertex Pharmaceuticals Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Vertex Pharmaceuticals Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30


cash flows from operating activities:
net income	-961,000	11,130,000	-67,798,000	7,221,000	5,164,000	2,684,000	15,334,000	-3,399,000	-6,896,000	-18,132,000	-5,309,000	-1,141,000	-5,520,000	-334,000	-627,000	-3,948,000	808,000	2,288,000	230,000	-21,028,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	23,428,000	22,266,000	21,285,000	20,118,000	20,382,000	20,948,000	19,294,000	18,407,000	17,248,000	16,942,000	15,825,000	14,793,000	17,629,000	12,906,000	12,880,000	14,205,000	8,881,000	8,816,000	8,629,000	8,170,000
amortization of cloud computing implementation costs	1,018,000	1,006,000	1,013,000	1,005,000	995,000	994,000	1,020,000	919,000
benefit from subscription cancellations and non-renewals	-328,000	192,000	669,000	-921,000	-631,000	1,082,000	676,000	33,000												-102,000
amortization of deferred financing costs	681,000	680,000	688,000	685,000	514,000	146,000	77,000	63,000	63,000	63,000	64,000	63,000	65,000	53,000	52,000	53,000	53,000	53,000	17,000	-72,000
change in fair value of contingent consideration liabilities	2,500,000	-14,700,000	17,200,000	100,000	-1,575,000	-800,000
change in settlement value of deferred purchase commitment liability			0	0
write-off of deferred financing costs			0	0							0	0	-2,000	372,000					36,000
stock-based compensation expense	11,990,000	21,044,000	10,966,000	10,135,000	10,000,000	16,324,000	7,691,000	7,772,000	7,022,000	11,434,000	5,346,000	5,256,000	4,194,000	4,933,000	5,910,000	7,422,000	6,285,000	6,543,000	7,014,000	64,294,000
deferred income taxes	-712,000	-929,000
non-cash operating lease costs	816,000	779,000	819,000	502,000	708,000	828,000	732,000	1,230,000	-101,000	726,000	909,000	914,000	912,000	622,000	958,000	1,000,000	869,000	998,000
other	-64,000	-7,000	-52,000	14,000	-59,000	-106,000	5,480,000	-78,000	-63,000	-4,000	3,343,000	157,000	140,000	412,000	230,000	214,000	80,000	-14,000	21,000	72,000
changes in operating assets and liabilities:
accounts receivable	10,548,000	11,772,000	-37,669,000	-4,137,000	15,252,000	4,478,000	-14,462,000	-248,000	-29,717,000	-795,000	-8,087,000	-6,678,000	-13,588,000	2,688,000	-9,158,000	1,127,000	-2,817,000	13,810,000	-10,905,000	-2,950,000
prepaid expenses and other current assets	-237,000	-13,169,000	-3,962,000	-11,214,000	8,304,000	-7,335,000	-6,874,000	165,000	2,464,000	-2,109,000	2,251,000	659,000	-2,033,000	-1,091,000	-1,523,000	-273,000	10,041,000	-13,437,000	3,072,000	-2,896,000
deferred commissions	-202,000	-56,000	-4,940,000	-677,000	-561,000	-64,000	-4,142,000	-369,000	-804,000	-459,000	-1,706,000	-1,589,000	-488,000	875,000	28,000	-1,038,000	148,000	50,000	-1,371,000	17,000
accounts payable	5,393,000	-11,279,000	7,080,000	3,870,000	1,818,000	-1,153,000	-808,000	2,394,000	4,590,000	3,065,000	1,263,000	-4,626,000	3,177,000	1,555,000	2,318,000	-986,000	257,000	2,258,000	-3,035,000	-1,718,000
accrued expenses	3,490,000	2,956,000	-11,472,000	2,170,000	5,465,000	-8,486,000	-4,028,000	-7,542,000	-171,000	17,578,000	8,951,000	5,428,000	-3,121,000	3,806,000	5,655,000	3,262,000	-2,659,000	-3,048,000	3,186,000	2,863,000
accrued and deferred compensation	-2,981,000	-26,785,000	6,200,000	11,692,000	5,855,000	-14,515,000	5,029,000	13,192,000	1,747,000	-12,452,000	440,000	5,105,000	1,704,000	-19,254,000	-3,056,000	7,622,000	6,665,000	-14,966,000	4,767,000	5,405,000
deferred revenue	-8,782,000	11,156,000	41,685,000	1,360,000	-3,126,000	11,177,000	27,149,000	-10,156,000	-3,173,000	4,352,000	25,518,000	-1,038,000	10,006,000	-3,718,000	26,662,000	-751,000	3,826,000	-5,046,000	25,808,000	-898,000
operating lease liabilities	-989,000	-1,068,000	-1,143,000	-775,000	-956,000	-1,125,000	-1,361,000	-1,141,000	-413,000	-1,309,000	-1,204,000	-969,000	-1,105,000	-763,000	-1,012,000	-1,153,000	-1,013,000	-1,519,000
payments for purchase commitment and contingent consideration liabilities in excess of initial fair value			0	0
net cash from operating activities	46,003,000	14,805,000	41,133,000	41,396,000	57,726,000	24,566,000	47,636,000	27,594,000	-7,653,000	6,755,000	43,820,000	18,450,000	11,981,000	2,595,000	39,301,000	26,203,000	29,430,000	-2,965,000	39,499,000	-712,000
capex	-4,904,000	-5,661,000	-4,987,000	-5,260,000	-5,482,000	-5,615,000	-4,889,000	-5,041,000	-5,035,000	-4,007,000	-4,600,000	-4,362,000	-3,014,000	-2,912,000	-3,758,000	-2,777,000	-2,904,000	-2,221,000	-2,604,000	-1,982,000
free cash flows	41,099,000	9,144,000	36,146,000	36,136,000	52,244,000	18,951,000	42,747,000	22,553,000	-12,688,000	2,748,000	39,220,000	14,088,000	8,967,000	-317,000	35,543,000	23,426,000	26,526,000	-5,186,000	36,895,000	-2,694,000
cash flows from investing activities:
acquisition of businesses and assets, net of cash acquired			0
long-term investment
property and equipment additions	-21,512,000	-21,394,000	-18,249,000	-17,771,000	-15,300,000	-14,449,000	-13,904,000	-13,498,000	-8,546,000	-13,313,000	-15,557,000	-15,146,000	-13,954,000	-13,873,000	-9,487,000	-8,011,000	-9,693,000	-6,195,000	-5,973,000	-4,417,000
capitalized software additions	-4,904,000	-5,661,000	-4,987,000	-5,260,000	-5,482,000	-5,615,000	-4,889,000	-5,041,000	-5,035,000	-4,007,000	-4,600,000	-4,362,000	-3,014,000	-2,912,000	-3,758,000	-2,777,000	-2,904,000	-2,221,000	-2,604,000	-1,982,000
purchase of investment securities, available-for-sale	0	-2,398,000	-3,747,000	-4,470,000	-3,505,000	-4,271,000	-3,464,000	-4,437,000	-4,936,000	-3,491,000	-10,391,000
proceeds from sales and maturities of investment securities, available-for-sale	0	11,607,000	2,100,000	5,750,000	4,060,000	4,800,000	2,350,000
net cash from investing activities	-41,416,000	-17,846,000	-24,883,000	-85,431,000	-28,302,000	-19,535,000	-19,907,000	-15,536,000	-13,167,000	-17,561,000	-25,184,000	-18,692,000	-23,911,000	-17,259,000	-13,245,000	-68,609,000	-200,088,000	-14,516,000	-7,829,000	-6,399,000
cash flows from financing activities:
net increase in customer funds obligations	-6,720,000	3,227,000	3,643,000	-8,947,000	-960,000	15,939,000	-11,386,000	2,523,000	3,484,000	10,989,000	-8,737,000	1,968,000	-5,617,000	1,046,000	-4,518,000	-3,483,000	22,665,000	-438,000	523,000	-1,464,000
proceeds from convertible senior notes			0	0
principal payments on long-term debt			0	0	-46,250,000	-625,000	-625,000	-625,000	-625,000	-313,000	-313,000	-312,000							-222,000	-175,020,000
payment for purchase of capped calls			0	0
payments for deferred financing costs			-1,167,000	0	-11,285,000	-89,000					0	0	10,000	-993,000					0	468,000
proceeds from purchases of stock under espp			1,555,000	0			1,308,000	0			984,000	0			1,050,000	0
payments for taxes related to net share settlement of stock-based awards	-1,071,000	-25,034,000	-1,526,000	-1,666,000	-462,000	-17,862,000	-491,000	-5,224,000	-305,000	-3,681,000	-92,000	-523,000	-152,000	-337,000	-46,000	-1,997,000	-3,537,000	-7,178,000
proceeds from exercise of stock options	6,521,000	1,166,000	3,770,000	1,415,000	1,764,000	1,510,000	1,742,000	854,000	753,000	1,490,000	533,000	570,000	118,000	600,000	647,000	821,000	244,000	147,000	2,785,000	5,971,000
payments for purchase commitment and contingent consideration liabilities			0	0			0	0
payments of finance lease liabilities	-16,000	-12,000	-23,000	-19,000	-25,000	-26,000	-26,000	-50,000	-11,000	-16,000	-1,258,000	-47,000
net cash from financing activities	496,000	-20,653,000	6,252,000	-13,121,000	239,279,000	-1,153,000	-20,479,000	-2,522,000	-1,950,000	-1,531,000	-8,883,000	-8,512,000	-5,291,000	39,780,000	-3,146,000	-14,693,000	16,880,000	-8,140,000	1,197,000	229,052,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	1,997,000	1,310,000	-1,822,000	1,599,000	-440,000	-349,000	779,000	-435,000	176,000	204,000	785,000	-525,000	-529,000	-83,000	-45,000	-213,000	5,000	-226,000	390,000	-208,000
net increase in cash, cash equivalents and restricted cash	7,080,000	-22,384,000	20,680,000	-55,557,000	268,263,000	3,529,000			-22,594,000	-12,133,000			-17,750,000	25,033,000	22,865,000			-25,847,000	33,257,000
cash, cash equivalents and restricted cash, beginning of period	0	326,066,000	0	0	0	89,151,000	0	0	0	106,748,000	0	0	0	98,206,000	0	0	0	312,273,000	0	0
cash, cash equivalents and restricted cash, end of period	7,080,000	303,682,000	20,680,000	-55,557,000	268,263,000	92,680,000	8,029,000	9,101,000	-22,594,000	94,615,000	10,538,000	-9,279,000	-17,750,000	123,239,000	22,865,000	-57,312,000	-153,773,000	286,426,000	33,257,000	221,733,000
reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets, end of period:
cash and cash equivalents	13,991,000	270,395,000	17,072,000	-46,556,000	269,401,000	56,134,000	18,676,000	7,634,000	-26,778,000	68,643,000	19,433,000	-13,184,000	-11,786,000	97,340,000	25,852,000	-54,112,000	-176,088,000	277,681,000	32,780,000	222,976,000
restricted cash—funds held for customers	-6,911,000	33,287,000	3,608,000	-9,001,000	-1,138,000	36,546,000	-10,647,000	1,467,000	4,184,000	25,972,000	-8,895,000	3,905,000	-5,964,000	25,899,000	-2,987,000	-3,200,000	22,315,000	8,745,000	477,000	-1,243,000
total cash, cash equivalents and restricted cash, end of period	7,080,000	303,682,000	20,680,000	-55,557,000	268,263,000	92,680,000	8,029,000	9,101,000	-22,594,000	94,615,000	10,538,000	-9,279,000	-17,750,000	123,239,000	22,865,000	-57,312,000	-153,773,000	286,426,000	33,257,000	221,733,000
proceeds from term loan											0	0	0	50,000,000
payments on third-party debt			0
distributions under tax sharing agreement											0	0	0	-536,000	0	0
payments for deferred purchase commitments							-10,000,000	0	0	-10,000,000	0	-10,000,000	0	-10,000,000
reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets, end of period:
deferred income tax benefit				1,087,000	-7,114,000	-2,588,000					-1,325,000	68,000	-150,000	62,000	-41,000	-263,000	-2,197,000	-615,000
acquisition of assets, net of cash acquired
acquisition of business, net of cash acquired											0	0	0	-474,000			-187,491,000	-6,100,000	748,000	0
change in fair value of contingent consideration liability								900,000	249,000	200,000		1,300,000	0	700,000
deferred income tax								2,297,000
net decrease in cash, cash equivalents and restricted cash
proceeds from maturities of investment securities, available-for-sale									5,350,000	3,250,000
benefit from subscription cancellations and non-renewals, net of deferred allowance										697,000	-225,000	640,000	-332,000	-279,000	43,000	-571,000	615,000	379,000
deferred income tax (benefit) expense										-12,984,000
redemption of converted sars																			0
proceeds from line of credit																			0	0
principal payments on line of credit																			0	0
proceeds from issuance of shares in connection with offering																			0
payments for offering costs																			0
payments for taxes on exercised stock options
distributions to stockholders																			-32,000	-5,706,000
payments for purchase commitment liabilities											0	-168,000			0
purchase of investment securities, available for sale
proceeds from long-term debt																			0	0
purchase of treasury stock
acquisition of businesses, net of cash acquired
payments for taxes on exercised options
payments on finance lease liabilities																0
advances to stockholders																				228,000
payments for purchase commitment liability
payments on financing lease liabilities																		-671,000
restricted cash—funds held for stockholder distributions
impairment of asset

We provide you with 20 years of cash flow statements for Vertex Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Vertex Pharmaceuticals stock. Explore the full financial landscape of Vertex Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Vertex Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.